Abstract
Secondary osteoporosis is a frequent complication of rheumatoid arthritis (RA) and the result of an imbalance of catabolic and anabolic mechanisms of bone metabolism. The effects of serial low-dose radon and hyperthermia (LDRnHT) exposure in a therapeutic adit (12 applications in 3 weeks) on the serum levels of the cytokines osteoprotegerin (OPG), receptor activator of NF kappa-B ligand (RANKL), tumor necrosis factor-α (TNF-α), and also on the RANKL/OPG ratio were investigated in 25 RA patients and an age-matched control of 24 patients with osteoarthritis (OA). Cytokine measurements were performed at baseline and after completion of LDRnHT. Anti-CCP antibodies (ACPA) were measured in RA patients in parallel. Medication in both groups was limited to non-steroidal anti-inflammatory drugs, and low-dose prednisolone (16 of 24 RA patients) as needed. RA and OA patients showed a significant decrease of TNF-α levels (p < 0.001). Both groups showed significantly decreased levels of RANKL (RA: p < 0.001, OA: p < 0.01). Only the RA patients presented a significant increase of OPG (p < 0.01) and decrease of the RANKL/OPG ratio (p < 0.01), and the ACPA levels (p < 0.001). LDRnHT results in a reduction of osteocatabolic and an increase of osteoanabolic cytokines, which represents the molecular basis for inhibiting osteoclastic activity in secondary osteoporosis and explains in part the effect of LDRnHT this physical therapy modality in a key inflammatory disease. Although reduced ACPA levels were observed under the therapy and although this could potentially contribute to an osteoprotective effect, in this case, it is rather uncertain as the reduction was only minor in magnitude.



Similar content being viewed by others
References
Schmidt KL, Simon E (2001) Thermotherapy of pain, trauma and inflammatory and degenerative rheumatic diseases. In: Kokoaska M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 527–539
Falkenbach A (2001) Combined radon and heat exposure for treatment of rheumatic diseases. In: Kokoaska M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 495–503
Kürten B Radon (stollen) therapie: Bewährtes und Neues. In: Lange U (ed) Physikalische Medizin in der Rheumatologie—unter Berücksichtigung evidenzbasierter Daten. Rheuma Wissen, Ligatur, Stuttgart, pp 179–188
Schwarzmeier J, Shehata M et al (2003) Increased levels of TGF-beta 1 in patients with ankylosing spondylitis after spa therapy. European Cytokine Network vol 14, Supp l
Becker K (2004) One century of radon therapy. Int J Low Radiat 1(3):333–357
Tarner I, Uhlemann C, Müller-Ladner U, Lange U (2009) The effect of serial mild whole-body hyperthermia on the responsiveness of plasma cytokine levels of TNF-α, Interleukin 1-β and interleukin 6 in patients with ankylosing spondylitis and a healthy population. Clin Rheumatol 28:397–402
Falkenbach A, Kovacs J, Franke A et al (2005) Radon therapy for the treatment of rheumatic diseases—review and meta-analysis of controlled clinical trials. Rheumatol Int 5:205–210
Van Tubergen A, Landewe R, van der Heijde D et al (2001) Combined spa exercise therapy is effective in ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 45:430–438
Moder A, Hufnagl C, Lind-Albrecht G et al (2010) Effect of combined low-dose radon and hyperthermia treatment (LDRnHT) of patients with ankylosing spondylitis on serum levels of cytokines and bone metabolism markers: a pilot study. Int J Low Radiat 7(6):423–435
Lange U, Neumann N, Kürten B et al (2012) The impact of serial low-dose radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in ankylosing spondylitis. Phys Med Rehab Kuror 22:203–206
Dischereit G, Neumann N, Kürten B et al (2014) The impact of serial low-dose radon hyperthermia exposure on pain, disease activity and pivotal cytokines of bone metabolism in ankylosing spondylitis—a prospective study. Akt Rheumatol 39:304–309
Lange U, Neumann E (2009) Bone and inflammation—molecular mechanisms, new pathophysiological relevant metabolic pathways and future innovative therapies. Osteologie 1:41–44
Dischereit G, Lange U (2014) Osteoporosis—inflammatory effects on bone metabolism and fracture risk. Z Orthop Unfall 152:170–176
Neumann E, Gay S, Müller-Ladner U (2005) The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 52:2960–2967
Lange U (2012) Molecular physical medicine. Z Rheumatol 71:381–386
Keck AL, Pecherstorfer M (2003) Knochenstoffwechsel bei malignen Erkrankungen. J Miner Stoffwechs 10:6–11
Lange U, Dischereit G, Neumann E et al (2015) Osteoimmunological aspects on inflammation and bone metabolism. J Rheum Dis Treat 1:008
Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427–435
Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92:4514–4521
Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208:228–251
Zwerina J, Hayer S, Tohidast-Akrad M et al (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50:277–290
Lange U, Obermayer-Pietsch B (2009) Genetic aspects of osteoporosis in ankylosing spondylitis. Z Orthop Unfall 147:577–581
Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802
Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268
Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192
Kong YY, Feige U, Sarosi I et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309
Petitt AR, Walsh NC, Manning C et al (2006) RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosions in rheumatoid arthritis. Rheumatology 45:1068–1076
Fonseca JE, Cortez-Dias N, Francisco A et al (2005) Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 23:185–192
Kim HR, Kim HY, Lee SH (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 45:1197–1200
Lubberts E (2008) IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41(2):84–91
Acknowledgments
We thank the Gasteiner Kur, REHA- and HeilstollenbetriebsgesmbH for the possibility to carry out the study, and Angelika Moder from the Gastein Research Institute for advice. They had no role in the study design, data collection and analysis, data interpretation, the writing of the manuscript, or the decision to submit the manuscript for publication.
Authors’ contributions
UL and BK conceived and designed the study. UL, KF, and EN carried out the ELISA assays. UL, GD, and IT performed the statistical analysis. UL, GD, KF, and UML interpreted the data. UL, KF, and UML drafted the manuscript. All authors revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Ethical standards
The study was conducted in cooperation with the Gastein Research Institute and was carried out in parallel following a recently published pilot study [9] approved by the ethics committee of the state of Salzburg, Austria, and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its alter amendments. Owing to the Salzburg ethics committee, approval needed to be given on oral basis as no medication was needed. However, according to data recording rules all patients submitted written consent forms, and all patients screened for participation in the study agreed to take part and fully completed the study.
Rights and permissions
About this article
Cite this article
Lange, U., Dischereit, G., Tarner, I. et al. The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis. Clin Rheumatol 35, 2783–2788 (2016). https://doi.org/10.1007/s10067-016-3236-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-016-3236-7